Resultados de la búsqueda 41-50 of 3856 for 搜索引擎推广优化机构,种子引擎搜索,俄罗斯第二搜索引擎,游戏要怎么推广,外贸网站开发多少钱等欢迎访问六五Ai站群搜尋引擎系統V.25.05.20官方网站:www.65.hk
Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...
... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype: triple negative [HER2, estrogen and progesterone receptor (ER and PR) all negative] ...
... 2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a ...
This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...
Obtén más información sobre los ensayos clínicos que se llevan a cabo en Mayo Clinic para lograr avances en el tratamiento y en los resultados para personas ...
The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancer types are: Non-Small Cell Lung ...
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
3 to 5 years. 5 to 10 adenomas or adenoma with villous features or high-grade dysplasia, 3 years. More than 10 adenomas, 1 year. Atención en Mayo Clinic.
Scottsdale/Phoenix, Ariz. The purpose of this Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial study is to assess post ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?